Revo Capital

Revo Capital is Istanbul’s largest VC firm, operating around $188M in AUM across multiple funds with Fund II closing at EUR90M and Fund III now active. The firm explicitly added Health IT as a sector in Fund II and writes Seed, Series A, and Series B checks in the $1M to $5M range. Its healthcare credibility is anchored by Massive Bio, the AI-enabled oncology clinical trial platform, which has been one of Revo’s higher-profile bets and demonstrates that the fund can underwrite sophisticated AI models for clinical trials and diagnostics. The right founder for Revo is a Turkish or Turkish-diaspora technical operator building a B2B SaaS, cloud, or AI platform with credible international ambition, often US or EU as the eventual primary market. The fund’s portfolio reach into Eastern Europe and the Baltics also opens doors that pure-Turkey funds cannot. Healthcare relevance includes clinical AI, diagnostic imaging models, oncology and trials infrastructure, hospital and clinic SaaS, and AI applications layered onto multi-language European clinical and claims data. Founders pursuing biotech, devices with multi-year FDA pathways, or pure consumer wellness should look at specialist funds. Geographic advantage is the regional cross-border network, the Turkish technical talent pool that combines strong ML training with reasonable burn rates, and Revo’s institutional credibility with global Tier-1 co-investors at Series B and beyond. Best entry is a warm intro from a portfolio founder or a known regional co-investor; cold inbound is read but conversion is lower. Lead the pitch with the data asset, model evaluation rigor, and a credible international go-to-market plan, since serious Turkish healthcare AI bets eventually need to land US, UK, or EU customers to scale. AI founders should be ready to discuss FDA or CE strategy, multi-language model performance, and clinical validation pathways. Caveats: lira volatility shapes cap table conversations and operating budgets, and savvy Turkish founders structure rounds with FX hedging and dollar-denominated holding structures. Ask Revo about reserves, prorata behavior, and which Series B leads have followed it into portfolio companies. Confirm the fund’s deployment pace and vintage, and reference current portfolio CEOs on operating support and cross-border introductions. Used appropriately, Revo is the most credible Turkish institutional partner for healthcare AI founders building toward international scale.